3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Rhabdoid Tumor
1
Neoplasms, Squamous Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Adult Solid Neoplasm
1
Interventions
Radiotherapy
4
Radiation
4
Nivolumab
4
Ipilimumab
3
CTLA-4 Antigen
3
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Biopsy
2
talimogene laherparepvec
1
pazopanib
1
futibatinib
1
fludarabine
1
cabozantinib
1
aldesleukin
1
Ifosfamide
1
Erlotinib Hydrochloride
1
Doxorubicin
1
Cyclophosphamide
1
BO-112
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Histiocytoma, Malignant Fibrous
×
Erlotinib Hydrochloride
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled